pmid	doi	year	title	Hugo_Symbol
34110462	10.1007/s00277-020-04357-z	2021	Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR-ABL1 and its resistance and compound mutants BCR-ABL1<sup>T315I</sup> and BCR-ABL1<sup>T315I-E255K</sup>.	ZFAT
